Pharmacokinetics
The pharmacokinetic data suggested that once-daily nevirapine dosing resulted in lower minimum nevirapine plasma concentrations compared with twice-daily treatment.
However these studies theoretically support once-daily dosing assuming that optimal adherence is maintained.
Figure 1. Median steady-state plasma concentration vs time curves of nevirapine in 20 HIV-1-infected patients after administration of nevirapine 400 mg once-daily (solid circles) and 200 mg twice-daily (open circles).
[van Heeswijk RP et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14: F77–F82]
The median nevirapine plasma concentration at the end of the dosing interval (Cmin) was about 23% lower during once-daily dosing compared with twice-daily dosing [2.88 µg/mL (2.33–4.09 µg/mL) vs 3.73 µg/mL (3.20–5.08 µg/mL), respectively; P<0.01].
Parts of this CME:
start of the CME
Clinical pharmacology of NVP
2NN: efficacy
Other clinical sudies on NVP QD efficacy
Transition from BID to QD: clinical data
The future
Conclusions